First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age
Line M Lindgren, Pernille N Tingskov, Annette H Justesen, Bettina S Nedergaard, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Charlotte Sørensen, Jes Dietrich, Birgit Thierry-Carstensen, Line M Lindgren, Pernille N Tingskov, Annette H Justesen, Bettina S Nedergaard, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Charlotte Sørensen, Jes Dietrich, Birgit Thierry-Carstensen
Abstract
Background: There is a demand of affordable IPV in the World. Statens Serum Institut (SSI) has developed three reduced dose IPV formulations adsorbed to aluminium hydroxide; 1/3 IPV-Al, 1/5 IPV-Al and 1/10 IPV-Al SSI, and now report the results of the first investigations in humans.
Methods: 240 Danish adolescents, aged 10-15years, and childhood vaccinated with IPV were booster vaccinated with 1/3 IPV-Al, 1/5 IPV-Al, 1/10 IPV-Al or IPV Vaccine SSI. The booster effects (GMTRs) of the three IPV-Al SSI were compared to IPV Vaccine SSI, and evaluated for non-inferiority.
Immunogenicity results: The pre-vaccination GMTs were similar across the groups; 926 (type 1), 969 (type 2) and 846 (type 3) in the total trial population. The GMTRs by poliovirus type and IPV formulation were: Type 1: 17.0 (1/3 IPV-Al), 13.0 (1/5 IPV-Al), 7.1 (1/10 IPV-Al) and 42.2 (IPV Vaccine SSI). Type 2: 12.5 (1/3 IPV-Al), 13.1 (1/5 IPV-Al), 7.6 (1/10 IPV-Al) and 47.8 (IPV Vaccine SSI). Type 3: 14.5 (1/3 IPV-Al), 16.2 (1/5 IPV-Al), 8.9 (1/10 IPV-Al) and 62.4 (IPV Vaccine SSI) Thus, the three IPV-Al formulations were highly immunogenic, but inferior to IPV Vaccine SSI, in this booster vaccination trial.
Safety results: No SAE and no AE of severe intensity occurred. 59.2% of the subjects reported at least one AE. Injection site pain was the most frequent AE in all groups; from 24.6% to 43.3%. Injection site redness and swelling frequencies were<5% in most and<10% in all groups. The most frequent systemic AEs were fatigue (from 8.2% to 15.0%) and headache (from 15.0% to 28.3%). Most AEs were of mild intensity. In conclusion, the three IPV-Al SSI were safe in adolescents and the booster effects were satisfactory. ClinicalTrials.gov registration number: NCT02280447.
Keywords: Affordable IPV; Aluminium hydroxide adjuvant; Dose investigation; IPV dose sparing.
Copyright © 2016. Published by Elsevier Ltd.
Figures
References
- World Health Organisation. Polio eradication & endgame strategic plan 2013-2018. WHO Press World Health Organisation, 20 Avenue Appia, Geneva, Switzerland 2013. Available from: URL: <>.
- Okayasu H., Sutter R.W., Jafari H.S., Takane M., Aylward R.B. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;1(210 Suppl 1):S459–S464. [November]
- Estivariz C.F., Pallansch M.A., Anand A. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol. 2013;3(3):309–315. [June]
- Brenzel L. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries? Vaccine. 2015;7(33 Suppl 1):A93–A98. [May]
- Introduction of inactivated poliovirus vaccine and switch from trivalen to bivalent oral poliovirus vaccine - worldwide, 2013–2016. MMWR Recomm Rep 2016 March 7. Vol. 64 (25). p. 699–702.
- Bonnet M.C., Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine. 2008;26(39):4978–4983. [September 15]
- Wilson J. The ethics of disease eradication. Vaccine. 2014;32(52):7179–7183. [December 12]
- Polio vaccines: WHO position paper, January 2014–recommendations. Vaccine, vol. 32(33); 2014. p. 4117–8 [July 16].
- Andreasen L.V., Hansen L.B., Andersen P., Agger E.M., Dietrich J. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats. Vaccine. 2015;17(33):1873–1879. [February]
- Plotkin S.A., Liese J., Madhi S.A., Ortiz E. A DTaP-IPV//PRP approximately T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev Vaccines. 2011;10(7):981–1005. [July]
- Vergara R., Tregnaghi M., Ussher J. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr. 2005;164(6):377–382. [June]
- Haastrup E., Thierry-Carstensen B., Jensen A.M., Stellfeld M., Heilmann C. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells. Vaccine. 2004;22(8):958–962. [February 25]
- Pietrzyk J.J., Wysocki J., Pejcz J. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age. Vaccine. 2008;26(41):5296–5303. [September 26]
- Thierry-Carstensen B., Dalby T., Stevner M.A., Robbins J.B., Schneerson R., Trollfors B. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults-A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013;28(31):5178–5191. [August]
- Melnick J., Wenner H.A., Philips C.A. American public health association Inc.; Washington, DC: 1976. Enteroviruses. Diagnostic procedures for viral, rickettsial and chlamydial infections.
- Vidor E, Plotkin S. Poliovirus vaccine - inactivated. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th ed.; 2013. p. 573–97.
- Aggerbeck H., Wantzin J., Heron I. Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations–III. Vaccine. 1996;14(13):1265–1272. [September]
- Gajdos V., Vidor E., Richard P., Tran C., Sadorge C. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV. Vaccine. 2015;33(32):3988–3996. [July 31]
- Embree J., Law B., Voloshen T., Tomovici A. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart. Clin Vaccine Immunol. 2015;22(3):282–290. [March]
- Bergfors E., Hermansson G., Nystrom K.U., Falk L., Valter L., Trollfors B. How common are long-lasting, intensely itching vaccination granulomas and contact allergy to aluminium induced by currently used pediatric vaccines? A prospective cohort study. Eur J Pediatr. 2014;173(10):1297–1307. [October]
Source: PubMed